⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16095100 | 1.00 | — | — | |
| SCHEMBL25497642 | 1.00 | — | — | |
| SCHEMBL8154925 | 0.93 | — | — | |
| SCHEMBL2299460 | 0.90 | — | — | |
| SCHEMBL29964047 | 0.88 | ALDH1A1 (0.47) | — | |
| SCHEMBL30229369 | 0.88 | ALDH1A1 (0.47) | — | |
| SCHEMBL13032778 | 0.88 | ALDH1A1 (0.47) | — | |
| SCHEMBL31714042 | 0.88 | ALDH1A1 (0.47) | — | |
| SCHEMBL30229481 | 0.88 | ALDH1A1 (0.47) | — | |
| SCHEMBL1755945 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-10294248-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2018-09-27 | — | — | US | disclosed |
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170145037-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-05-25 | — | — | US | disclosed |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2016-01-28 | — | — | US | disclosed |
| EP-2970340-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150361108-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
| WO-2014151958-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20070270357-A1 | Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270357-A1 | Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |